Cassava Sciences, Inc. (NASDAQ:SAVA) Shares Bought by Two Sigma Investments LP

Two Sigma Investments LP increased its position in shares of Cassava Sciences, Inc. (NASDAQ:SAVA - Free Report) by 679.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 562,082 shares of the company's stock after acquiring an additional 489,936 shares during the quarter. Two Sigma Investments LP owned approximately 1.17% of Cassava Sciences worth $1,327,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently bought and sold shares of SAVA. MYDA Advisors LLC purchased a new stake in shares of Cassava Sciences during the fourth quarter worth approximately $400,000. XTX Topco Ltd purchased a new position in Cassava Sciences in the fourth quarter worth $220,000. Aristides Capital LLC raised its position in Cassava Sciences by 588.6% in the fourth quarter. Aristides Capital LLC now owns 62,542 shares of the company's stock worth $148,000 after acquiring an additional 75,342 shares in the last quarter. Raymond James Financial Inc. purchased a new position in Cassava Sciences in the fourth quarter worth $147,000. Finally, BNP Paribas Financial Markets raised its position in Cassava Sciences by 638.0% in the fourth quarter. BNP Paribas Financial Markets now owns 64,561 shares of the company's stock worth $152,000 after acquiring an additional 55,813 shares in the last quarter. Institutional investors and hedge funds own 38.05% of the company's stock.

Analysts Set New Price Targets

Separately, HC Wainwright restated a "neutral" rating and issued a $2.00 price target on shares of Cassava Sciences in a research report on Tuesday, March 25th.

Cassava Sciences Stock Performance

Cassava Sciences stock traded up $0.07 during midday trading on Friday, reaching $2.19. 1,063,224 shares of the company were exchanged, compared to its average volume of 3,024,029. The company has a market capitalization of $105.79 million, a price-to-earnings ratio of -1.59 and a beta of -1.99. Cassava Sciences, Inc. has a 1 year low of $1.15 and a 1 year high of $42.20. The firm's 50-day simple moving average is $1.70 and its 200-day simple moving average is $2.68.

Cassava Sciences (NASDAQ:SAVA - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.48) earnings per share for the quarter. On average, analysts forecast that Cassava Sciences, Inc. will post -3.97 EPS for the current fiscal year.

About Cassava Sciences

Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.